Exact SciencesEXAS
About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Employees: 7,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
123% more call options, than puts
Call options by funds: $251M | Put options by funds: $112M
1% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 88
0.22% more ownership
Funds ownership: 98.49% [Q3] → 98.71% (+0.22%) [Q4]
1% less funds holding
Funds holding: 585 [Q3] → 578 (-7) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 200
17% less capital invested
Capital invested by funds: $12.4B [Q3] → $10.3B (-$2.11B) [Q4]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Guggenheim Subbu Nambi 15% 1-year accuracy 3 / 20 met price target | 44%upside $60 | Buy Reiterated | 11 Apr 2025 |
Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target | 32%upside $55 | Overweight Maintained | 10 Apr 2025 |
Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target | 44%upside $60 | Outperform Initiated | 10 Apr 2025 |
RBC Capital Gerard Cassidy 27% 1-year accuracy 10 / 37 met price target | 25%upside $52 | Sector Perform Initiated | 13 Mar 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 68%upside $70 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 7 articles about EXAS published over the past 30 days
